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Available online 23 January 2016Brain glioblastoma and neurodegenerative diseases are still largely untreated due to the inability ofmost drugs to
cross the blood–brain barrier (BBB). Nanoparticles have emerged as promising tools for drug delivery applica-
tions to the brain; in particular carbon nanotubes (CNTs) that have shown an intrinsic ability to cross the BBB
in vitro and in vivo. Angiopep-2 (ANG), a ligand for the low-density lipoprotein receptor-related protein-1
(LRP1), has also shown promising results as a targeting ligand for brain delivery using nanoparticles (NPs).
Here, we investigate the ability of ANG-targeted chemically-functionalised multi-walled carbon nanotubes
(f-MWNTs) to cross the BBB in vitro and in vivo. ANG was conjugated to wide and thin f-MWNTs creatingw-
MWNT-ANG and t-MWNT-ANG, respectively. All f-MWNTswere radiolabelled to facilitate quantitative analyses
by γ-scintigraphy. ANG conjugation to f-MWNTs enhanced BBB transport ofw- and t-MWNTs-ANG compared to
their non-targeted equivalents using an in vitro co-cultured BBBmodel consisting of primary porcine brain endo-
thelial cells (PBEC) and primary rat astrocytes. Additionally, following intravenous administration w-MWNTs-
ANG showed signiﬁcantly higher whole brain uptake than the non-targeted w-MWNT in vivo reaching ~2%
injected dose per g of brain (%ID/g) within the ﬁrst hour post-injection. Furthermore, using a syngeneic glioma
model, w-MWNT-ANG showed enhanced uptake in glioma brain compared to normal brain at 24 h post-
injection. t-MWNTs-ANG, on the other hand, showed higher brain accumulation than w-MWNTs. However,
no signiﬁcant differences were observed between t-MWNT and t-MWNT-ANG indicating the importance
of f-MWNTs diameter towards their brain accumulation. The inherent brain accumulation ability of f-MWNTs
coupledwith improved brain-targeting by ANG favours the future clinical applications of f-MWNT-ANG to deliv-
er active therapeutics for brain glioma therapy.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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The blood–brain barrier (BBB) is a major obstacle for drug delivery to
the brain, limiting the number of drugs reaching the market to tackle
brain disorders [1]. Nanoparticles (NPs), providing a ﬂexible platform
for conjugating drugs and targeting ligands, have been extensively
researched to facilitate BBB crossing and effective delivery to the brain [2].
Carbonnanotubes (CNTs) have several attractive characteristics in this
regard, including ahigh aspect ratio, and the ability to penetrate biological
membranes due to their tubular shape [3]. f-MWNTs injected directly into
the brain led to a signiﬁcant reduction in neuronal damage in rats [4], and
also led to improved motor function recovery in an Endothelin-1 ratmal).
. This is an open access article understroke model via the successful delivery of caspase-3 siRNA to neurons
inmouse brain cortex [5]. f-MWNTs also improved the delivery of CpGol-
igonucleotide into glioma tumour cells using a single intracranial injection
[6]. In spite of the encouraging results, none of the above-mentioned stud-
ies utilised the systemic route of administration.
Recently we demonstrated the ability of f-MWNTs to cross the BBB
in vitro and in vivo [7]. The in vitroBBBmodel consists of primary porcine
brain endothelial cells (PBEC) co-culturedwith rat astrocytes. f-MWNTs
were visualised within endocytic vesicles of PBECs and crossed the
monolayer within 24 h. Following intravenous (i.v.) administration,
radiolabelled f-MWNT was also found to reach mouse brain without
the use of a targeting ligand.
The current study further explored f-MWNT as a brain delivery
nanocarrier by introducing a brain-targeting ligand Angiopep-2 (ANG)
to its surface [8]. ANG is a 2.4 kDa peptide of the Angiopep peptide fam-
ily which has a high afﬁnity for the low-density lipoprotein receptor-the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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in several tissues including brain capillary endothelium and gliomas
[9,10]. ANG exhibited signiﬁcantly greater transcytosis capacity across
bovine brain endothelial cells compared to transferrin, lactoferrin and
avidin [11]. Studies have shown that the direct conjugation of ANG to
drugs such as paclitaxel and neurotensin enhanced brain delivery, and
showed signiﬁcant tumour reduction and analgesic effects, respectively
[8,12]. ANG conjugation to NPs also showed signiﬁcant improvement in
brain delivery of polymeric micelles [13], dendrimers [14] and gold
nanoparticles [15]. Based on the reported success in previous studies,
we hypothesised that conjugating ANG to f-MWNT would improve its
BBB permeation and also facilitate brain tumour targeting in vitro and
in vivo.
f-MWNTs of two different diameters were employed in this study:
wide MWNTs (w-MWNTs, diameter 24.5 ± 1.7 nm, the f-MWNT used
in our previous study [7]) and thin MWNTs (t-MWNTs, diameter
7.8 ± 1.5 nm). The transport of non-targeted (w- and t-MWNT) and
targeted (w- and t-MWNT-ANG) f-CNTs was studied ﬁrstly using
the in vitro BBB co-culture model as previously reported [7]. In vivo
brain uptake of radiolabelled f-MWNTs was then studied by quantitative
γ-scintigraphy, 3D-single photon emission computed tomography/
computed tomography (SPECT/CT) imaging and autoradiography follow-
ing i.v. administration in normal and glioma-bearing mice.
2. Materials and methods
2.1. Materials
Pristine MWNTs, used for preparation of w-MWNTs (diameter 20–
30 nm; length 0.5–2.0 μm, batch #1237YJS) were purchased from Nano-
structured and Amorphous Materials Inc., USA. Pristine MWNTs used for
the preparation of t-MWNTs (diameter 9.5 nm; length 1.5 μm; batch
#NC3100) were purchased from Nanocyl s.a., Belgium. Reagents for
chemical functionalisation of f-MWNT, PBEC and astrocyte isolation and
culturing are listed in SI. Costar Transwell™ permeable 3.0 μmpore poly-
carbonate supportswere purchased fromCorning Inc., USA. Chemicals for
the Angiopep-2 synthesis, ﬂuoropore PTFE hydrophobic 0.22 μmmem-
brane and glutaraldehyde 25% aqueous solution were purchased from
Merck Millipore, UK. The radioactive tracer [111In]Cl3 was obtained from
Mallinckrodt Pharmaceuticals (Netherlands) as an aqueous solution in
0.5 M HCl and used without further puriﬁcation. Carbon/formvar coated
300-mesh copper grids were obtained from Agar Scientiﬁc, UK.
2.2. ANG synthesis by solid phase peptide synthesis (SPPS)
The synthesis of a modiﬁed ANG sequence (TFFYGGSRGKRNNFKTE
EYG) [8] was carried out using the CEM Liberty 1 microwave peptide
synthesiser (CEM Microwave Technology Ltd., UK) on NovaSyn®
TGR resin (0.5 mmol/g loading) as previously described [16]. Further
details on SPPS are provided in SI. Themolecularweight of the synthetic
ANG was conﬁrmed by matrix-assisted laser desorption/ionisation
time of ﬂight mass spectrometry (MALDI-TOF MS) (Bruker, USA)
using α-cyano-4-hydroxycinnamic acid as the matrix. ANG was also
characterised by reverse phase high-performance liquid chromatography
(RP-HPLC) using Vydac 218TP54 column (C8, 5 μm, 4.6 × 250 mm)
(Phenomenex, UK) with a water/acetonitrile gradient mobile phase con-
taining 0.1% TFA. The eluent was detected using a UV–vis detector at
280 nm.
2.3. Preparation of f-MWNT and conjugation with ANG
MWNT constructs were functionalised as described previously [7,
17]. Synthesis procedures are detailed in the SI Text and summarised
in Schemes 1 and 2. The synthesis of Boc- and phthalimide-protected
amino acids has been previously reported [18,19]. To conjugate ANG
to the surface of w- and t-MWNT-maleimide, 5 mg of MWNT 5 and 13were dispersed in PBS (4mMEDTA, 10mMTCEP, pH 6.5) and sonicated
for 10 min. ANG solution (3.4 μmol, 8.5 mg for MWNT 5 and 1.5 μmol,
3.7 mg for MWNT 13) was mixed with the MWNT 5 and 13, and the
reaction mixture was stirred for 60 h at room temperature. Multiple
centrifugation steps were carried out (15 min, 2916g) in water to re-
move the unreacted peptide from the solution. All conjugates were
characterised by thermogravimetric analysis (TGA) and Transmission
Electron Microscopy (TEM) as described in SI.
2.4. Radiolabelling of f-MWNT derivatives
f-MWNTs were radiolabelled with indium-111 (111In) as described
previously [7,17]. In brief, f-MWNT solutions (1 mg/ml in water) were
mixed with ammonium acetate buffer, yielding a ﬁnal acetate buffer
of 0.2 M, pH 5.5, to which 10 MBq of 111InCl3 was added. The reaction
was carried out for 30 min at room temperature, and terminated by
the addition of EDTA quenching solution (0.1 M, 1:20 v/v) to chelate
the unreacted 111In. The labelling efﬁciency was determined by thin
layer chromatography (TLC). TLC was carried out in 0.1 M ammonium
acetate mobile phase containing 50 mM EDTA, and allowed to dry be-
fore counting the signals using the Cyclone phosphor detector (Packard
Biosciences, UK). The spots at the application point of the TLC strips in-
dicated the presence of labelled f-MWNTs whereas the signals at the
solvent front were indicative of [111In]EDTA. Any unbound 111In was re-
moved by a centrifugation step (18,363g, 30min). The stability of the la-
belled materials was then tested by mixing with an equal volume of
serum and incubating at 37 °C for 24 h after labelling. Centrifugation
was performed to pellet f-MWNTs, which were re-suspended in sterile
PBS (1 mg/ml) to remove unbound 111In prior to in vitro and in vivo
studies.
2.5. Setting up the BBB co-culture Transwell™ system
A co-culture BBB model comprising PBECs and primary rat astro-
cytes was established in our previous study to assess the transport of
f-MWNTs in vitro [7]. The PBEC isolation method was originally devel-
oped by Rubin et al. [20], and further modiﬁed and improved by Abbott
and co-workers [21]. Primary astrocytes type I were isolated from 0 to
2 day old Wistar rat pups following the method of Abbott et al. [22].
Brieﬂy, astrocytes were cultured into a 12-well plate coated with
10 μg/ml poly-L-lysine one week before the experiment. PBECs were
cultured in T-75 ﬂasks initially and sub-cultured onto 3.0 μmpore poly-
carbonate inserts (Transwell™ ﬁlters) when the cells reached 50% con-
ﬂuence. The Transwell™ ﬁlters containing PBECs were placed in the
wells above the astrocytes. The cellswere incubated at 37 °C in a humid-
iﬁed chamber with 5% CO2. The trans-endothelial electrical resistance
(TEER) was measured (EVOM epithelial voltohmmeter with STX2 elec-
trode, World Precision Instruments, UK) to assess the tightness of the
BBB model. In vitro f-MWNTs transport studies were performed when
TEER values were N200 Ω·cm2.
2.6. Transport studies of f-MWNTs across the in vitro BBB model
Serum-free medium supplemented with tight junction growth
factors was replaced for 24 h before starting uptake studies to stimulate
the formation of tight junctions between adjacent endothelial cells [21].
111In-labelled f-MWNTs (20 μg/ml)were added to the apical chamber of
the Transwell inserts, and the platewas incubated at 37 °C up to 72 h. At
speciﬁed time points (1, 3, 5, 10, 15, 30, 45, 60, 120, 240, 1080, 2880 and
4320 min), 0.5 ml aliquots were taken from the basal chamber and
stored in counting vials. The medium in the basal chamber was
replenished with warm medium to maintain sink conditions. 111In sig-
nals were quantiﬁed as counts per minute (CPM) using a 1282
CompuGamma CS Gamma Counter (LKB Wallac, USA). Percentage
uptake was calculated from the total dose added to each well.
Results were expressed as mean ± S.D. (n = 3). The apparent
Scheme 1. Synthesis of w-MWNTs.
Scheme 2. Synthesis of t-MWNTs.
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equation [23];
Papp ¼ ΔCR  VRΔt  A  C0:
where ΔCR/Δt is the change in concentration in the receiving chamber
over time. This value was taken as the slope of the linear correlation
(concentration vs time) from short time point intervals (3 min–
60 min). C0 is the starting concentration in the donor chamber (CPM),
VR is the volume of the donor chamber (ml) and A is the surface area
of the Transwell™ ﬁlter (cm2).
2.7. Glioma cell culture
The GL261-Luc murine glioma cells (Caliper Life Sciences, UK) were
cultured in Advanced RPMImedia supplementedwith 10% FBS, 50Um/l
penicillin, 50 μg m/l streptomycin, 1% L-glutamine, at 37 °C in 5% CO2.
Cells were routinely grown in 75 cm2 tissue culture ﬂasks and passaged
twice a week at 80% conﬂuency using Trypsin/EDTA.
2.8. Organ biodistribution of f-MWNTs in mice by γ-scintigraphy
All in vivo experiments were conducted under the authority of Pro-
ject and Personal Licences granted by the UK Home Ofﬁce and the
UKCCCR Guidelines (1998). Female C57/Bl6 mice aged 5–6 weeks
were anaesthetised by isoﬂurane inhalation and intravenously (i.v.)
injected with radiolabelled f-MWNTs (50 μg, 0.5 MBq) via a tail-vein in-
jection. The bloodwas sampled at 2min, 5min, 30min, 1 h, 4 h and 24 h
after injection, and whole-body perfusion was performed on animals
using 25 ml of heparinised saline (1000 U/L) through the left ventricle
of the heart to wash out residual or loosely-bound f-MWNTs from the
blood vessels. Major organs including skin, liver, spleen, kidneys,
heart, lungs, muscle, bone, brain, stomach and intestine were then har-
vested at 5 min, 30 min, 1 h, 4 h and 24 h post-injection. For the collec-
tion of urine and faeces, the animals grouped for the 24-h time point
were caged individually in metabolic cages. Animals were starved but
with access to water for 24 h while urine and faeces were collected.
Excised organs were weighed and the radioactivity was measured by
γ-scintigraphy (LKB Wallac 1282 CompuGamma, PerkinElmer). The
results are expressed as % injected dose per organ (%ID, mean ± S.D.,
n= 3) or % injected dose per gram tissue (%ID/g, mean ± S.D., n= 3)
and were statistically analysed using one-way ANOVA.
2.9. Brain capillary depletion
Brain tissues were subjected to a further capillary depletion method
to separate the parenchyma from brain capillaries following a previous-
ly publishedmethod [24]. Each brain was placed in a glass homogeniser
in 0.8 ml of ice-cold depletion buffer (10 mM HEPES in HBSS, pH 7.4).
The brain was homogenised with 15 stokes of the pestle, and 1.6 ml of
depletion buffer, 26% dextran (148 kDa), was added into the
homogeniser. The brain was further homogenised with 3 strokes of
the pestle. Brain homogenate was centrifuged at 3220g for 15 min.
Brain parenchyma (supernatant) and brain vasculature (pellet) frac-
tions were separated and the radioactivity was measured using
gamma counting. The results are expressed as %ID per total brain capil-
laries or total brain parenchyma (mean ± S.D., n= 3) and statistically
analysed using one-way ANOVA. The area under the curve (AUC) was
calculated following the trapezoidal method by ﬁtting the data set to a
linear and log-linearmodel after 1 and 24 h, respectively [25]. The elim-
ination rate constant was extrapolated from plotting the changes in
concentrations versus time.2.10. SPECT/CT imaging
In vivo brain uptake of f-MWNTs was also examined by live SPECT/
CT imaging. Female C57/Bl6 mice aged 5–6 weeks were anaesthetised
by isoﬂurane inhalation and injected with f-MWNTs (50 μg, 7–
10 MBq) via a tail vein. SPECT/CT imaging was carried out at 0–
30 min, 4 h and 24 h post-injection in the prone position using the
NanoSPECT/CT scanner (Bioscan, USA). SPECT scanning was acquired
over 24 projections (60 s per projection) using a 4-head scanner with
1.4 mm pinhole collimators for a total acquisition time of 30–40 min.
CT scans were performed using a 45 kVP X-ray source after each
SPECT. SPECT images were reconstructed using HiSPECT (Scivis GmbH,
Germany) and CT images were reconstructed using InVivoScope, pro-
prietary Bioscan software. The two images were fused and analysed by
InVivoScope.
2.11. Autoradiography
To investigate the regional distribution of f-MWNT in brain, mice
were i.v. injected with f-MWNTs (50 μg CNT in 100 μl PBS, ~7 MBq),
and the brains were isolated at 5 min after injection for autoradiogra-
phy. Each brain was cut into 2 mm thick coronal sections using a
mouse brain slicer (Zivic-Miller, USA). Sections were placed between
two glass microscope slides, in contact with a super-sensitive plate
(Cyclone® storage phosphor screen, Packard) for ~17h in autoradiogra-
phy cassettes (Kodak BIomax Cassette®, Carestream Health Inc., UK),
which were then scanned using cyclone phosphor detector (Packard
Biosciences. UK).
2.12. Brain uptake of f-MWNTs in glioma-bearing mice
C57/Bl6 mice bearing intracranial GL261 glioma were prepared to
assess the brain uptake of f-MWNTs in a syngeneic glioma model. Fe-
male C57/Bl6 mice aged 6–8 weeks were anesthetised by isoﬂurane in-
halation and injected stereotactically with 1.25 × 105 GL261-Luc glioma
cells (3 μl in PBS) into the right hemisphere using a Hamilton syringe
(Harvard Apparatus, UK) with a 26-gauge needle at 0.2 μl/min. The ste-
reotactic coordinates relative to bregma were: 3mm anterior, 1 mm
lateral, 3 mm deep. Following surgery, in vivo quantitative biolumines-
cence imaging was performed twice a week to monitor the tumour
growth (IVIS Lumina III, Perkin-Elmer, UK). Mice under anaesthesia
were subcutaneously injected with luciferin (D-luciferin potassium
salt, Perkin-Elmer, UK) at 150 mg/kg and imaged 8 min after injection.
Bioluminescence signals from regions of interest were measured using
Living Image software (Perkin-Elmer, UK) and recorded as total ﬂux
(photons/s). Mice were i.v. injected with radiolabelled f-MWNTs when
tumours reached desired size roughly 2–3 weeks after tumour implan-
tation (total ﬂux N1 × 106 p/s). At 24 h post-injection, mice were per-
fused as described previously and brains were isolated and measured
by γ-scintigraphy.
3. Results
3.1. Characterisation of ANG peptide
A modiﬁed ANG peptide (TFFYGGSRGKRNNFKTEEYG) [8] was syn-
thesised using microwave-assisted SPPS and characterised with HPLC
and mass spectrometry. Fig. S1 A shows the structure of ANG with
propargylglycine (G20) conjugated to the C-terminal. The addition of
cysteine facilitates the conjugation to the modiﬁed f-MWNTs via
thiol–maleimide click reaction. Fig. S1 B shows the HPLC chromatogram
of ANG. A single peak was observed (retention time ~16.7 min)
conﬁrming the purity of ANG. The synthesised ANG was characterised
by MALDI-TOF mass spectrometry. The highest abundant ion in the
mass spectrometry chromatogram corresponds to 2499.13 m/z
221H. Kafa et al. / Journal of Controlled Release 225 (2016) 217–229(Fig. S1 B, inset), which corresponds to the predicted molecular weight
of ANG.
3.2. Functionalisation of w-MWNT and t-MWNT with ANG
The extremely small diameter of pristine t-MWNTsmakes them sus-
ceptible to aggregation in aqueous solution. Therefore, t-MWNTs were
initially oxidised in a mixture of sulphuric and nitric acid to increase
the water dispersibility. The acid treatment introduced carboxylic func-
tional groups on the side-walls of t-MWNT allowingmore efﬁcient sub-
sequent derivatisation with functional groups [17]. Pristine w- and
oxidised t-MWNTswere functionalised using 1, 3-dipolar cycloaddition.
t-MWNT was then subjected to amidation reaction as described previ-
ously. Details of the functionalisation steps are shown in Schemes 1
and 2 aswepreviously reported [7,17]. DTPAdianhydridewas conjugat-
ed to the amine terminal to chelate the radioactive tracer 111In used to
track f-MWNT in vitro and in vivo. The phthalimide-deprotected amines
were modiﬁed with a maleimide group to couple the thiol-modiﬁed
ANG via thiol–maleimide click reaction.
3.3. Characterisation of f-MWNTs
TGA was used to quantitatively monitor the functionalisation steps
of f-MWNTs. TGA relies on measuring the weight loss after heating the
sample to 1000 °C under N2 atmosphere. The weight loss is directly re-
lated to the introduction of functional groups onto the side-walls of f-
MWNTs. The weight loss was determined at 600 °C, the temperature
at which all the functional groups decompose, but below the decompo-
sition temperature of carbon nanotubes. Fig. S2 A and B show the TGA
proﬁles ofw-MWNTs and t-MWNTs, respectively. Themeasuredweight
loss and the corresponding functional group contents are summarised
in Table 1. The resulting degree of functionalisation for MWNT 6
(w-MWNTs-ANG) and 14 (t-MWNTs-ANG) were 31.2 and 7.6 μmol
ANG per gramme of CNTs, respectively.
TEM imaging was used to examine the structure of f-MWNTs before
and after coupling to ANG (Fig. 1). The images show no apparent struc-
tural differences after the coupling to ANG. The mean diameter/length
of the w-MWNTs and t-MWNTs measured from TEM images were
23.8 ± 2.1/494 ± 54 nm and 7.9 ± 1.8/437 ± 61 nm, respectively
(Table 1). The measured length of the f-MWNTs was shorter than the
pristine material due to acid treatment and/or the multiple ﬁltration
steps in the functionalisation process.
3.4. Radiolabelling of f-MWNTs
f-MWNT constructs were radiolabelled with 111In and the labelling
efﬁciency wasmeasured by TLC (Fig. S3). The results show the labelling
efﬁciency of ~21.5% and 7.0% for w-MWNTs and w-MWNTs-ANG
(Fig. S3 A),while higher labelling efﬁciency of ~85.6% and 82.1%was ob-
tained for t-MWNTs and t-MWNTs-ANG, respectively (Fig. S3 B). The
free 111In was removed by centrifugation where the labelled f-MWNTs
were pelleted while [111In]EDTA remained in the supernatant. MostTable 1
Functionalised f-MWNTs characteristics.
f-MWNTs f-MWNTs code
Mean diametera
(nm) ± S.D.
Mean lengtha
(nm) ± S.D.
Total functionalisa
(amidation + cycl
MWNT 4 w-MWNT 23.8 ± 2.1 494 ± 54 262 (0 + 262)
MWNT 5 – 23.8 ± 2.1 494 ± 54 262 (0 + 262)
MWNT 6 w-MWNT-ANG 23.8 ± 2.1 494 ± 54 262 (0 + 262)
MWNT 12 t-MWNT 7.9 ± 1.8 459 ± 61 837 (467 + 97)
MWNT 13 – 7.9 ± 1.8 459 ± 61 837 (467 + 97)
MWNT 14 t-MWNT-ANG 7.9 ± 1.8 459 ± 61 837 (467 + 97)
a Analysed by TEM measurements of f-MWNTs 4 and 13, for w-MWNTs and t-MWNTs, resp
b Analysed by TGA.labelled f-MWNTs remained stable (N75%) after 24 h of incubation in
50% serum at 37 °C (Fig. S3 C).
3.5. ANG conjugation improves f-MWNTs transport across the in vitro BBB
model
The amount of f-MWNTs that crossed the PBEC monolayer into the
basal chamber of the Transwell™ system over a 72 h incubation period
was assessed using 111In as a radioactive tracer. Fig. 2 shows that all stud-
ied f-MWNTs crossed the in vitro BBB model. The signals detected in the
basal chamber continually increased over time, reaching 15.6 ± 1.1%,
20.3 ± 0.9%, 7.6 ± 0.3% and 11.6 ± 0.9% of the total dose for w-MWNT,
w-MWNT-ANG, t-MWNT and t-MWNT-ANG, respectively, after 72 h of
incubation. In general, w-MWNTs achieved higher percentage transport
across the endothelial cells compared with t-MWNTs. Additionally, w-
MWNT-ANG and t-MWNT-ANG showed higher percentage transport
than their precursors over the studied time. Signiﬁcant increases were
observed by 2 h of incubation in the case ofw-MWNTs (p b 0.01), where-
as for t-MWNTs the difference became signiﬁcant by 18 h (p b 0.001).
The results indicate that conjugation of ANG to f-MWNTs led to a
signiﬁcant increase in transport across the PBEC monolayer irrespective
of f-MWNT diameter.
The apparent permeability coefﬁcient (Papp)was calculated for all con-
jugates (Table 2). The Papp of f-MWNTs was signiﬁcantly lower than that
of ANG alone and the free isotope [111In]EDTA, which suggested that f-
MWNTs cross the BBB at a lower rate than ANG alone. Thew-MWNTpre-
cursor achieved higher Papp (0.69± 0.16 × 10−6 cm/s) than the t-MWNT
(0.18 ± 0.01 × 10−6 cm/s) as shown in Table 2. This agreed with the
higher percentage transport obtained for w-MWNTs by 72 h. The conju-
gation of ANG increased the Papp of w- and t-MWNT-ANG to 1.26 ±
0.09 × 10−6 (54% increase) and 0.34 ± 0.02 × 10−6 cm/s (67% increase)
(Table 2), respectively. The studies above suggest that ANG improves f-
MWNT targeting to the BBB in vitro.
3.6. Organ biodistribution of f-MWNTs inmice following i.v. administration
Radiolabelled f-MWNTs were injected in C57/B16 mice via i.v. ad-
ministration and the biodistribution in themajor organs wasmonitored
at speciﬁc time points using gamma counting. Fig. 3A represents blood
proﬁles of f-MWNTs across the studied time points. w-MWNT-ANG
showed a signiﬁcant reduction in blood concentration compared to w-
MWNT at the early time points (12.5 ± 1.5 vs 6.7 ± 0.7%ID/g of blood
at 2 min, p b 0.001; 9.6 ± 3.3 vs 4.7 ± 0.5%ID/g of blood at 5 min,
p b 0.01)). The blood circulation proﬁles of the two w-MWNTs were
comparable for the rest of the time points and both decreased over
time until 24 h. Unlikew-MWNTs, t-MWNT and t-MWNT-ANG showed
a similar blood circulation proﬁle over the studied time points
(p N 0.05). The level in the blood also decreased over time by 24 h.
Figs. 3B and S4 show biodistribution proﬁles of f-MWNTs in the
major organs. Similar organ biodistribution proﬁles were observed for
all f-MWNTs conjugates with accumulation mainly in the lungs, liver
and spleen at all the studied time points. The non-targeted t-MWNTtion degree
oaddition)b (μmol/g CNTs)
DTPA loadingb (μmol/g CNTs)
Angiopep-2 loadingb
(μmol/g CNTs)
234 –
234 –
234 31.2
71 –
71 –
71 7.6
ectively. (n= 50).
Fig. 1. The structure of the f-MWNTs examined by transmission electron microscopy (TEM). f-MWNTs (1mg/ml in water) were deposited on carbon/formvar coated 300-mech grid and
imaged by TEM. Electron micrographs show thew-MWNTs (top row) and t-MWNTs (bottom row) before and after conjugation to ANG peptide. f-MWNTs showed no sign of structural
damage following the functionalisation reactions and the conjugation of ANG. The diameter and length of thew-MWNT and t-MWNTweremeasured from TEM images using NIH Imgae J
software (n= 50) and summarised in Table 1.
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agreeing with our previously published data [17].
The excretion proﬁles of f-MWNTswere examined bymeasuring the
radioactivity in urine and faeces collected over 24 h. Fig. S5 shows that
2–5%ID/g of f-MWNTs were found in urine, with negligible excretion
in faeces. There were no signiﬁcant differences between the excretion
proﬁles of the studied f-MWNTs.
3.7. w-MWNTs and t-MWNTs show different brain uptake proﬁles in vivo
The uptake of f-MWNTs into the whole brain, brain capillaries/
parenchyma and ratios of parenchyma to blood are shown in Fig. 4
(w-MWNTs shown in the left panel; t-MWNTs in the right panel).
w-MWNT-ANG achieved signiﬁcantly higher whole brain uptake
than w-MWNT at early time points up to 1 h post-injection (Fig. 4A
left). The highest uptake was measured as 2.0 ± 0.5 and 1.1 ± 0.3%ID/g
for w-MWNT-ANG and w-MWNT by 5 min post-injection, respectively.
Comparable accumulation in brain for both w-MWNTs was measured at
4 h, followed by a reduction until 24 h post-injection. The data indicated
that ANG conjugation signiﬁcantly enhanced the early whole brain up-
take of w-MWNTs.
Similar brain accumulation patterns were observed for the two t-
MWNTs in which high uptake was measured at early time points and
the values dropped gradually as a function of time (Fig. 4A right).
The uptake of t-MWNT and t-MWNT-ANG reached 2.6 ± 0.9%ID/g
and 3.1 ± 0.09%ID/g by 5 min post-injection, respectively. Neverthe-
less, t-MWNT-ANG did not show increased brain uptake over t-
MWNT. It should be noted that the two t-MWNTs achieved notablyhigher brain uptake compared to non-ANG-conjugated w-MWNT at
the studied period up to 1 h (p b 0.01). This was in agreement with
our previous study that t-MWNTs appear to possess intrinsic proper-
ties that resulted in higher brain uptake than w-MWNTs [17]. The
ﬁndings were also supported by the AUC calculations represented
in Table S1.
Capillary depletion was then used to separate brain capillaries from
the parenchyma. This allowed themeasurement of f-MWNT in each re-
spective fraction and to calculate the parenchyma to blood concentra-
tion ratio. Fig. 4B shows the amount of f-MWNTs in the capillary
fraction. The difference of the uptake in the capillary fraction between
w-MWNT and w-MWNT-ANG was signiﬁcant by 1 h post-injection
(0.17 ± 0.03 vs 0.4 ± 0.07%ID/capillaries, p b 0.05, Fig. 4B left). The
amount decreased over the time course of the experiment. In the
parenchyma fraction (Fig. 4C left),w-MWNT-ANG showed signiﬁcantly
greater parenchyma accumulation (0.3 ± 0.07%ID/parenchyma) than
w-MWNT (0.08 ± 0.01%ID/parenchyma) by 5 min post-injection
(p b 0.01).
In the case of t-MWNTs, there was no signiﬁcant difference between
the two in their uptake in either parenchyma or capillaries at all studied
time points (Fig. 4B–C right). The amounts detected in the capillaries for
both t-MWNTs were sustained up to 4 h at levels above 0.4%ID, before
dropping by 24 h post-injection. t-MWNT and t-MWNT-ANG reached
parenchyma with substantial amounts at 5 min post-injection (0.4 ±
0.1 and 0.5 ± 0.2%ID, respectively). In fact, both t-MWNTs showed sig-
niﬁcantly higher uptake in parenchyma compared tow-MWNTs at early
time point post-injection (i.e. 5 min and 30 min, p b 0.01). Additionally,
both t-MWNTs showed increased accumulation in capillaries up to 4 h
Fig. 2. Transport of f-MWNTs across the in vitro BBB model over 72 h. Radiolabelled
f-MWNTs (20 μg/ml) were added to the apical chamber and incubated with PBEC at
37 °C for 72 h. The radioactivity of (A) w-MWNT and w-MWNT-ANG and (B) t-MWNT
and t-MWNT-ANGwas detected in the basal chamber after crossing the PBEC monolayer.
Solutions of 0.5ml aliquotswere sampled from the basal chamber at different time points.
Insets to the right show the transport of f-MWNTs during the initial 4 h of incubation.
Values are presented as mean ± S.D. (n = 3) with statistics analyses using One-way
ANOVA test. ** p b 0.01; *** p b 0.001.
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the results overall suggested that the greater overall brain uptake for f-
MWNTs was associated with enhanced uptake in both brain parenchy-
ma and capillary fractions during early time points.
Differences in brain accumulation between conjugates are also
expressed as parenchyma to blood ratios (P/B) calculated over the
time course of the study (Fig. 4D). The values are generally used to as-
sess the distribution of compounds in the brain parenchyma following
systemic administration [26]. P/B ratios for t-MWNTs were generally
higher than those of w-MWNTs at the studied period. The highest P/B
ratios for the t-MWNT and t-MWNT-ANG were measured at 30 min
post-injection (0.68 ± 0.34 and 1.04 ± 0.44, respectively) which were
statistically higher than the values obtained for both w-MWNT and w-
MWNT-ANG (p b 0.05). The results suggested a greater parenchymadis-
tribution of t-MWNTs over w-MWNTs, particularly at early times post-
injection. In addition, ANG brain targeting effect was only evident in
the case of w-MWNTs.
The negative values of the elimination rate constant (Kel) obtained
forw-MWNT andw-MWNT-ANG suggest better parenchymal retention
of these conjugates compared to t-MWNTs (Table 3). Also, the Kel
values of all f-MWNTswere higher in brain capillaries than parenchymaTable 2
Apparent permeability coefﬁcient (Papp) of f-MWNTs across PBEC.
w-MWNT w-MWNTs-ANG t-M
Papp (cm/s) × 10−6 0.69 ± 0.16 1.26 ± 0.09 0.18fractions. This observation shows that the majority of brain clearance is
taking place from the capillaries while f-MWNTs that reached the pa-
renchyma exhibit evidence of relative brain retention.
3.8. f-MWNTs show better accumulation in midbrain regions
The ability of radiolabelled w-MWNTs and t-MWNTs to accumulate
in mouse brain after systemic administration was also studied using
SPECT/CT imaging. Fig. 5A shows the brain accumulation of w-
MWNTs.w-MWNT-ANGshowedhigher accumulation in the brain com-
pared to w-MWNT by 30 min and 4 h following injection. The signals
decreased after 24 h suggesting the clearance of w-MWNTs from brain
(111In decay has been compensated).
Both targeted and non-targeted t-MWNTs achieved higher brain ac-
cumulation compared to their w-MWNT equivalents within 30 min of
injection (Fig. 5B). Intense signals were detected in the brain for both
t-MWNT and t-MWNT-ANG, with no apparent differences being detect-
ed. The intensity of the signals decreased after 4 h and diminished fur-
ther after 24 h.
Autoradiography provided further evidence on the region-speciﬁc
brain accumulation of w- and t-MWNTs. For w-MWNTs, w-MWNT-
ANG showed higher signals compared to w-MWNT after 5 min,
matching the previous ﬁndings in SPECT/CT and gamma counting (Fig.
6A). Both t-MWNT and t-MWNT-ANG showed high autoradiography
signal after 5 min (Fig. 6B). The highest signals in all studied f-MWNTs
were localised to the thalamic region of the brain (c3–c5). It should be
noted that mice were injected with f-MWNTs labelled with similar but
not exactly the same radioactivity. Hence, direct comparison of the sig-
nals in different brain sections of the same brain (same f-MWNTs) can
bemade but not sections betweendifferent brains (different f-MWNTs).
3.9. ANG conjugation improves w-MWNTs uptake in glioma-bearing brains
Finally, it was important to investigate whether the conjugation with
ANG can enhance the brain uptake ofw-MWNTs in glioma-bearing mice
since LRP1 receptor is expressed on BBB and glioma [10,11] Radiolabelled
w-MWNTs were i.v. injected into GL261 glioma-bearing mice or normal
mice and the brain uptake proﬁles were assessed quantitatively by γ-
scintigraphy at 24 h post-injection. As shown in Fig. 7, the non-targeted
w-MWNT displayed higher uptake in glioma brain (0.35 ± 0.01%ID/g)
compared to normal brain (0.18 ± 0.01%ID/g, p= 0.001). Interestingly,
w-MWNT-ANG exhibited markedly higher brain uptake in glioma brain
(0.77 ± 0.17%ID/g) than normal brain (0.24 ± 0.05%ID/g, p b 0.01). Fur-
thermore, a signiﬁcantly enhanced uptake in glioma-brain was obtained
for w-MWNT-ANG compared to w-MWNT (p b 0.05). No signiﬁcant dif-
ference between the two w-MWNTs in normal brains was obtained at
24 h post-injection. Unexpectedly, no signiﬁcant differences between t-
MWNTand t-MWNT-ANG innormal brain or gliomabrainwere observed
at 24 h post injection. It is not clear whether the higher elimination rate
constant (Kel) values reported for t-MWNT than w-MWNT are the main
reason for the lack of tumour retention, especially since measurements
were taken at 24 h post-injection.
4. Discussion
The BBB is the main obstacle hindering the delivery of NPs to the
brain using systemic administration. Several targeting ligands have
been explored for NP-mediated brain targeting including transferrin
[27], insulin [28], lactoferrin [29], OX26 monoclonal antibody [30] and
apolipoprotein E [31]. ANG is another brain ligand which binds toWNT t-MWNT-ANG Angiopep-2 [111In]EDTA
± 0.01 0.34 ± 0.02 8.69 ± 1.53 1.03 ± 0.06
Fig. 3. Blood and organ biodistribution proﬁles of radiolabelled f-MWNTs following i.v. administration. The blood proﬁles of f-MWNTs are shown in (A) and biodistribution of f-MWNTs in
major organs is shown in (B). f-MWNTs were injected (50 μg, 0.5 MBq) into the tail vein of C57/Bl6 mice. Blood was sampled at 5 min, 30 min, 1 h, 4 h and 24 h, and then a whole body
perfusion with heparinised saline was performed before sacriﬁce to remove residual f-MWNTs from circulation. Major organs were harvested and the radioactivity of all the samples was
measured using gamma counting. Insets to the left show amagniﬁed view of the brain uptake over the studied time points. Data are presented as % injected dose per gram tissue (%ID/g).
Values are expressed as mean ± S.D. (n= 3), and analysed using One-way ANOVA test. ** p b 0.01; *** p b 0.001.
224 H. Kafa et al. / Journal of Controlled Release 225 (2016) 217–229LRP1, amultifunctional receptor initially known to be associatedwith li-
poprotein metabolism, and degradation of proteases [9,32]. The in-
volvement of LRP1 in vasculature protection, cell migration and BBB
integrity regulation was characterised later. Being engaged in several
essential signalling mechanisms, LPR1 is expressed in a wide range of
tissues, as well as in neurons, astrocytes [33,34] and brain capillaries
[11]. LRP1 is continually endocytosed from themembrane and recycled
back [9], which makes it an attractive target for BBB crossing. Studies
have shown that ANG exhibited signiﬁcantly greater transcytosis capac-
ity across bovine brain endothelial cells compared to transferrin,
lactoferrin and avidin [11]. Strategies of direct conjugation of drugs to
ANG have also been developed. LRP1 is abundant in many cancer cells
and plays roles in oncogenesis, tumour progression and metastasis
[32]; ANG has been reported to enhance brain delivery of paclitaxel, in-
creasing the survival time of glioblastoma-bearing mice [8]. ANG has
also been used for brain delivery of neurotensin to enhance analgesic re-
sponse in rats [12]. Despite the success in direct coupling drug to ANG,
to increase the drug payload, work has also been conducted to conju-
gate ANG to NPs such as polymeric micelles [13], dendrimers [14] and
gold nanoparticles [15] for advanced brain delivery.We previously reported that the diameter of f-MWNTs directly
affects their biodistribution proﬁles [17]. In our recent work, we
studied the behaviour of f-MWNTs, referred to here as w-MWNT, at
the BBB interface. w-MWNT was found within brain parenchyma
by 5 min following i.v. administration without the use of a targeting
ligand [7]. The present work studied the effect of ANG conjugation to
f-MWNTs of different diameters on the transport across the BBB
in vitro and in vivo. The brain uptake of w-MWNTs and t-MWNTs
with or without ANG conjugation was investigated in normal and
glioma-bearing mice after i.v. administration. We hypothesised
that targeting f-MWNTs to LRP1 receptor via ANG conjugation
would offer superior BBB crossing and therefore brain accumulation
compared to non-targeted f-MWNTs. Furthermore, ANG-conjugated
f-MWNTs would favour glioma tumours over healthy brain tissues
in vivo.
Both w- and t-MWNT-ANG clearly showed signiﬁcant increases in
the percentage transport across PBEC compared tow- and t-MWNT, in-
dicating the ANG targeting effect in vitro. Also, interestingly, regardless
of ANG conjugation, w-MWNTs showed superior percentage transport
across the in vitro BBB model compared to t-MWNTs. The enhanced
Fig. 4. Uptake of radiolabelled f-MWNTs into mouse brain following i.v. administration and capillary depletion. Overall brain uptake of f-MWNTs is shown in (A) expressed as % injected
dose per gram of brain (%ID/g). The radioactivity of f-MWNTs in brain capillaries (B) and parenchyma (C)wasmeasured after capillary depletion with the data presented as %ID per total
brain capillaries or parenchyma. Their accumulation in blood (%ID/g) versus parenchyma (%ID/g) is shown in (D). The weight of parenchyma was considered as the weight of the whole
brain in this case. f-MWNTswere injected (50 μg, 0.5 MBq) into the tail vein of C57/Bl6 mice. Whole body perfusion with heparinised saline was performed to remove residual f-MWNTs
from circulation. The total brain accumulation wasmeasured by gamma counting followed by capillary depletion at 5 min, 30min, 1 h, 4 h and 24 h. Values are expressed asmean± S.D.
(n= 3) and analysed using One-way ANOVA test. * p b 0.05; ** p b 0.01.
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after 2 h of incubation while the targeting effect took place after longer
incubation time (i.e. 18 h) in the case of t-MWNTs.
Based on our previous report elucidating the mechanisms of f-
MWNTs transport across the in vitro BBB model [7], it is unlikely that
f-MWNTs enter the cells via a receptor-mediated mechanism as the di-
mension is too large for this route (N500 nm in length) to be utilised.
However, coupling ANG to f-MWNTs may possibly provide anchoringpoints to the LRP1 receptor on the cell surface and thereby increase
the cellular uptake of targeted w-MWNT-ANG and t-MWNT-ANG.
In vivo results showed that w-MWNT-ANG exhibited a signiﬁcant
improvement over w-MWNT in overall brain uptake up to 1 h post-
injection. Capillary depletion revealed that the enhancement in whole
brain uptake for w-MWNT-ANG at earlier time points was due to the
higher accumulation in the brain parenchyma and capillaries compared
to non-targeted w-MWNT.
Table 3
Elimination rate constant (Kel) of f-MWNTs in brain.
MWNT type
Whole brain
(hour−1)a
Capillaries
(hour−1)a
Parenchyma
(hour−1)a
w-MWNT 0.053 ± 0.008 0.066 ± 0.016 −0.026 ±−0.013
w-MWNT-ANG 0.060 ± 0.013 0.092 ± 0.026 −0.005 ±−0.001
t-MWNT 0.058 ± 0.013 0.102 ± 0.032 0.034 ± 0.011
t-MWNT-ANG 0.107 ± 0.031 0.135 ± 0.035 0.019 ± 0.005
a The data expressed as mean ± SD, n= 3.
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t-MWNTs in their accumulation in thewhole brain, capillaries or paren-
chyma. There are several possible reasons for the lack of targeting effectFig. 5. In vivo SPECT/CT imaging of f-MWNTs inmouse brain. Sagittal views of radiolabelled (A)
MWNTs were injected (50 μg, 5–7 MBq) into the tail vein of C57/Bl6 mice. In vivo 3D SPECT/CTof t-MWNT-ANG in vivo. Both t-MWNTsmayhave reached a level of sat-
uration in brain capillaries right after injection. As shown in Fig. 4B, sig-
niﬁcantly higher %ID/capillaries was measured for both t-MWNTs
compared to non-targeted w-MWNT up to 4 h post-injection. The
targeting effect of ANGmight be surpassed by the higher intrinsic ability
of t-MWNTs to cross the BBB. It is also worth mentioning that the
amount of ANG loading on t-MWNT-ANG was ~4 fold lower than for
w-MWNT-ANG which might have been insufﬁcient to enhance the
brain uptake in vivo.
In addition to the uptake enhancement imparted by ANG conjuga-
tion, f-MWNTs themselves play a major role in determining the extent
of uptake in brain. Studies in a non-BBB environment have shown that
rod-shaped nanoparticles achieved greater uptake into a humanw-MWNTs and (B)w-MWNTs inmouse brains at 0–30min, 4 h and 24 h post injection. f-
imaging was carried out at speciﬁed time posts post i.v. injection.
Fig. 6. Autoradiography of f-MWNTs inmouse brain. Autoradiographs of brain sections frommice injected withw-MWNTs (A) and t-MWNTs (B) at 5 min post-injection. f-MWNTs were
injected (50 μg, 5–7MBq) into the tail vein of C57/Bl6mice. Brainswere harvested at 5min post-injection and sectioned in coronal orientation fromolfactory bulbs to brainstem into 2mm
thick sections (c1–c6).
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difference in aspect ratios [35,36]. Accordingly, the tubular-shaped f-
MWNTs and their high aspect ratios (~58 and ~30 for t-MWNTs and
w-MWNT, respectively) might explain their ability to reach the brain
parenchyma after i.v. injection in quantities higher than the values re-
ported for other NPs of lower aspect ratios.
Even without active targeting, a maximum in vivo brain uptake for
non-targeted w- and t-MWNTs was 1.1 ± 0.3 and 2.4 ± 0.9%ID/g of
brain, respectively. The values were several fold higher than those re-
ported for non-targeted liposomes ~0.138 ± 0.03%ID/g [37], ANG-
targeted polymeric micelles ~0.6%ID/g [13], ANG-modiﬁed dendrimers
~0.25%ID/g [14,27] and non-targeted polymersomes ~0.3%ID/g [38].
The highest brain accumulation in our study was measured by 5 min
post-injection (with perfusion in place) compared with other systems
which generally showed the highest brain uptake between 1 and 4 h
post-injection.
As mentioned previously, ANG can be utilised as a ‘doubled-
targeting’ ligand, to target not only the BBB but also brain tumours.Many studies have developed ANG-tailored NPs as nanocarriers to
achieve efﬁcient drug delivery to brain tumours. It has been reported
that ANG-conjugated cationic liposomes successfully co-delivered ther-
apeutic DNA and paclitaxel to glioma in vivo, resulting in longer survival
time than controls and even commercial temozolomide treatments. Ren
et al. have investigated the effect of ANG on f-MWNT in which f-MWNT
was coated with ANG-conjugated polyethylene glycol (PEG) and also
incorporated doxorubicin (Dox). Optical imaging showed superior
brain accumulation and prolonged survival time for Dox-MWNT-PEG-
ANG compared to Dox-MWNT-PEG or Dox alone in glioma-bearing
mice [39]. ANG-modiﬁed gold nanoparticles have been shown to signif-
icantly enhance tumour accumulation of Dox in glioma-bearing mice
and increased survival time compared to non-targeted NPs or Dox
alone [15]. It isworthmentioning that none of the above studies provide
quantiﬁcation of NPs in glioma brain but relied on semi-quantitative
ﬂuorescence imaging of doxorubicin or ﬂuorescent liposomes. By con-
trast, the present study quantiﬁed the brain accumulation of the
nanocarriers directly.
Fig. 7. Brain uptake of f-MWNTs in glioma-bearing mice following i.v. administration.
w-MWNT,w-MWNT-ANG, t-MWNT, t-MWNT-ANGwere intravenously injected (50 μg,
0.5 MBq) into normal or GL261 glioma-bearing C57/Bl6mice. Whole body perfusion with
heparinised salinewas performed to remove residual f-MWNTs from circulation. The total
brain accumulation was measured by gamma counting at 24 h post-injection.
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right after injection then decreasing as a function of time. An altered
brain uptake pattern was observed for w-MWNTs in the glioma
model. At 24 h after injection, both w-MWNTs exhibited higher brain
uptake in glioma-bearing mice than normal mice. The slight increase
of w-MWNT lacking ANG in glioma brain could be due to a relatively
disrupted BBB [40]. ANG-mediated targeting and/or retention in glioma
brain could account for the substantial amount of w-MWNT-ANG
(~0.8%ID/g) measured at 24 h post-injection compared to non-
targetedw-MWNT (~0.38%ID/g). t-MWNTs, on the other hand, showed
lower glioma accumulation than w-MWNTs after 24 h. This could be
due to the thinner diameter of t-MWNTs that led to faster clearance
rate from the brain glioma. Further, studies of time-course in combina-
tion with imaging are required to understand how ANG inﬂuences
glioma targeting of f-MWNTs.
5. Conclusions
ANG conjugation to both w- and t-MWNT signiﬁcantly enhanced
their transport across the PBEC monolayer in vitro. However, in vivo,
ANG conjugation signiﬁcantly increased brain uptake of w-MWNT but
not t-MWNT. The latter, however, exhibited intrinsically higher brain
uptake, with and without ANG conjugation. Furthermore, w-MWNT-
ANG exhibited enhanced uptake in glioma brain compared to non-
targeted conjugate, supporting the use of ANG-conjugated f-MWNTs
for effective drug delivery to brain tumours.
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